Research in the William Checkley Lab explores the field of lung health, with an emphasis on the epidemiology of obstructive lung diseases as well as acute lung injury and mechanical ventilation. We also explore the interactions between nutrition and infection, and the impact of environmental exposures to health.

Dr. Wu leads a multi-disciplinary team with collaborators from the Bloomberg School of Public Health, JHU Whiting School of Engineering, and JHU Krieger School of Arts and Sciences. She conducts ongoing investigations with the Multicenter AIDS Cohort Study and Women’s Inter-agency Health Study. Her lab’s goals are to develop, implement, and validate novel imaging-based metrics of cardiac structure and function to improve risk prediction and stratification at the individual patient-level. Research Focuses: Predictors of Sudden Cardiac Death by Magnetic Resonance Imaging Subclinical myocardial disease in people living with HIV Individualized risk prediction Cardiac structural and mechanical modeling

The William Bishai Laboratory studies the molecular pathogenesis of tuberculosis. The overall goal of our laboratory is to better understand tuberculosis pathogenesis and then to employ this understanding toward improved drugs, vaccines and diagnostics. Since Mycobacterium tuberculosis senses and adapts to a wide array of conditions during the disease process, it is clear that the regulation of expression of virulence factors plays an important role in pathogenesis. As a result, a theme of our research is to assess mycobacterial genes important in gene regulation. We are also interested in cell division in mycobacteria and the pathogenesis of caseation and cavitation.

The goals of the Vikram Chib Lab are to understand how the nervous system organizes the control of movement and how incentives motivate our behaviors. To better understand neurobiological control, our researchers are seeking to understand how motivational cues drive our motor actions. We use an interdisciplinary approach that combines robotics with the fields of neuroscience and economics to examine neuroeconomics and decision making, motion and force control, haptics and motor learning, image-guided surgery and soft-tissue mechanics.

The mission of the laboratory of vestibular neurophysiology is to advance the understanding of how the body perceives head motion and maintains balance - a complex and vital function of everyday life. Although much is known about the vestibular part of the inner ear, key aspects of how the vestibular receptors perceive, process and report essential information are still mysterious. Increasing our understanding of this process will have tremendous impact on quality of life of patients with vestibular disorders, who often suffer terrible discomfort from dizziness and vertigo. The laboratory group's basic science research focuses on the vestibulo-ocular reflexes - the reflexes that move the eyes in response to motions of the head. They do this by studying the vestibular sensors and nerve cells that provide input to the reflexes; by studying eye movements in humans and animals with different vestibular disorders, by studying effects of electrical stimulation of vestibular sensors, and by using mathematical models to describe these reflexes. Researchers are particularly interested in abnormalities of the brain's inability to compensate for vestibular disorders.

The Veit Stuphorn Laboratory studies the neurophysiological mechanisms that underlie decision making and self-control. We record the activity of single neurons in awake animals that are engaged in decision-making processes. This allows us to identify the types of signals that neurons in specific parts of the brain represent and the computations they carry out. We also study human subjects in the same tasks with the help of fMRI. These parallel experiments provide comparative information about decision processes in human and non-human primates.

Research in the Vestibular NeuroEngineering Lab (VNEL) focuses on restoring inner ear function through “bionic” electrical stimulation, inner ear gene therapy, and enhancing the central nervous system’s ability to learn ways to use sensory input from a damaged inner ear. VNEL research involves basic and applied neurophysiology, biomedical engineering, clinical investigation and population-based epidemiologic studies. We employ techniques including single-unit electrophysiologic recording; histologic examination; 3-D video-oculography and magnetic scleral search coil measurements of eye movements; microCT; micro MRI; and finite element analysis. Our research subjects include computer models, circuits, animals and humans. For more information about VNEL, click here. VNEL is currently recruiting subjects for two first-in-human clinical trials: 1) The MVI Multichannel Vestibular Implant Trial involves implantation of a “bionic” inner ear stimulator intended to partially restore sensation of head movement. Without that sensation, the brain’s image- and posture-stabilizing reflexes fail, so affected individuals suffer difficulty with blurry vision, unsteady walking, chronic dizziness, mental fogginess and a high risk of falling. Based on designs developed and tested successfully in animals over the past the past 15 years at VNEL, the system used in this trial is very similar to a cochlear implant (in fact, future versions could include cochlear electrodes for use in patients who also have hearing loss). Instead of a microphone and cochlear electrodes, it uses gyroscopes to sense head movement, and its electrodes are implanted in the vestibular labyrinth. For more information on the MVI trial, click here. 2) The CGF166 Inner Ear Gene Therapy Trial involves inner ear injection of a genetically engineered DNA sequence intended to restore hearing and balance sensation by creating new sensory cells (called “hair cells”). Performed at VNEL with the support of Novartis and through a collaboration with the University of Kansas and Columbia University, this is the world’s first trial of inner ear gene therapy in human subjects. Individuals with severe or profound hearing loss in both ears are invited to participate. For more information on the CGF166 trial, click here.

The principal goal of LEADD is to catalyze the development and dissemination of innovative techniques in advanced gastrointestinal endoscopy at Johns Hopkins Medical Institutions, by providing the resources and expertise to conceptualize, design, build, and test new endoscopic devices. LEADD resources will also provide resources for endoscopy education for trainees and faculty. Additional Faculty: Anthony Kalloo, M.D.; Mouen Khashab, M.D., Saowanee Ngamruengphong, M.D. 

Dr. Cebotaru is the Director of Johns Hopkins Center for Gene Therapy research in Gastroenterology and research in the Cebotaru Lab studies cystic fibrosis transmembrane conductance regulator (CFTR) mutants as well as the pathophysiology of polycystic liver and kidney disease (PKD). They also investigate corrector molecules to get a better understanding of their mechanism of action. A major focus of her research is on developing more efficient gene therapy vectors with the ultimate goals of developing a gene therapy for cystic fibrosis and PKD.

Research in the Lilly Engineer Lab examines the quality and safety of medical care, with a focus on rural and underserved communities. Our current research evaluates methods for improving immunization rates among inner-city populations of school-aged children. We are also exploring the effect of federal policy changes and health care market forces on rural hospitals in the United States.